Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Neoplasm Metastasis 2Urogenital Neoplasms 1Solitary Fibrous Tumors 1Sarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 9Biopsy 5Specimen Handling 4Prednisone 4Nivolumab 4Magnetic Resonance Spectroscopy 4fludarabine 3Vincristine 3Etoposide 3Doxorubicin 3Brentuximab Vedotin 3sodium-iodide symporter 2pembrolizumab 2fludarabine phosphate 2cemiplimab 2alectinib 2X-Rays 2Whole-Body Irradiation 2Stem Cell Transplantation 2Rituximab 2Positron-Emission Tomography 2Photons 2Mycophenolic Acid 2Immunoglobulin G 2Filgrastim 2Disulfides 2Cyclosporine 210-propargyl-10-deazaaminopterin 2treosulfan 1talimogene laherparepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × Suspensions × 1 year × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡